Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sapporo Clinical Laboratory's quarterly Accounts Payable
increased
from Sep. 2024 (円2,128 Mil) to Mar. 2025 (円2,154 Mil) and
increased
from Mar. 2025 (円2,154 Mil) to Sep. 2025 (円2,196 Mil).
Sapporo Clinical Laboratory's annual Accounts Payable
increased
from Mar. 2023 (円2,179 Mil) to Mar. 2024 (円2,236 Mil) but then
declined
from Mar. 2024 (円2,236 Mil) to Mar. 2025 (円2,154 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Accounts Payable Chart
Sapporo Clinical Laboratory Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Sapporo Clinical Laboratory (SSE:9776) has a Accounts Payable of 円2,196 Mil as of Sep. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sapporo Clinical Laboratory and its competitors.
Is Sapporo Clinical Laboratory's Accounts Payable too high?
Sapporo Clinical Laboratory's current Accounts Payable is 円2,196 Mil. Overall, Sapporo Clinical Laboratory has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Accounts Payable compare to competitors?
Sapporo Clinical Laboratory's Accounts Payable of 円2,196 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Healthcare Providers & Services company?
A good Accounts Payable depends on the Healthcare Providers & Services industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sapporo Clinical Laboratory and its competitors. Sapporo Clinical Laboratory's current Accounts Payable is 円2,196 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (SSE:9776) has a current Accounts Payable of 円2,196 Mil. The stock's GF Value™ is 円1,128.61, compared to a current price of 円2,124.00 — trading 88.2% above its estimated fair value. The current Accounts Payable is 円2,196 Mil. Sapporo Clinical Laboratory's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sapporo Clinical Laboratory (SSE:9776), the current Accounts Payable is 円2,196 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (SSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円2,124.00 is trading 88.2% above its estimated GF Value™ of 円1,128.61.
Key valuation signals for SSE:9776:
Accounts Payable: 円2,196 Mil
GF Value™: 円1,128.61 vs. price of 円2,124.00 (88.2% above fair value)
No single metric tells the full story. See the SSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
66GF Score
Get the complete analysis for SSE:9776
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSE:9776 has been successfully added to your 
